A total of 38 abstracts, including seven oral presentations, will be presented from a broad range of studies in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
'At AbbVie, we have a focused vision of improving the care and advancing treatment options for people living with rheumatic diseases, which is illustrated by the body of research that will be presented at this year's ACR meeting,' said
Data evaluating the long-term safety and efficacy of RINVOQ in rheumatoid arthritis will be presented, including: 84-week data on RINVOQ as a monotherapy in patients with inadequate response to methotrexate
72-week RINVOQ monotherapy data in methotrexate-naive patients
72-week data comparing RINVOQ versus HUMIRA in patients with inadequate response to methotrexate
An integrated safety update reflecting up to three years of treatment with RINVOQ
Oral presentations will also highlight the safety and efficacy of RINVOQ in the treatment of psoriatic arthritis (through 24 weeks) and ankylosing spondylitis (through 64 weeks), while a poster presentation will provide a new integrated safety analysis from two Phase 3 trials evaluating the safety profile of RINVOQ in psoriatic arthritis.
Further, several presentations will show patient-reported outcomes for RINVOQ in the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, including its impact on pain reduction and physical function.
About RINVOQ (upadacitinib)
Discovered and developed by AbbVie, RINVOQ is a selective and reversible JAK inhibitor that is being studied in several immune-mediated inflammatory diseases.1-3 In
About AbbVie in Rheumatology
For more than 20 years, AbbVie has been dedicated to improving care for people living with rheumatic diseases. Our longstanding commitment to discovering and delivering transformative therapies is underscored by our pursuit of cutting-edge science that improves our understanding of promising new pathways and targets in order to help more people living with rheumatic diseases reach their treatment goals.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words 'believe,' 'expect,' 'anticipate,' 'project' and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, failure to realize the expected benefits from AbbVie's acquisition of
Contact:
Tel: +1 (224) 244-3808
Email: lindsay.cangemi@abbvie.com
(C) 2020 Electronic News Publishing, source